#USA #New York #Bryan Jones #AARD stock #Aardvark Inc

Aardvark Therapeutics Faces Securities Class Action

Aardvark Therapeutics, Inc. (NASDAQ: AARD) is currently embroiled in a significant securities class action lawsuit following allegations of misleading statements made by its former Chief Operating Officer, Bryan Jones, Ph.D. The claims relate to the company’s flagship product, ARD-101, which is aimed at treating specific health conditions, such as obesity from certain underlying diseases. The class action lawsuit covers Aardvark securities purchased between February 13, 2025, and May 14, 2026, and could have substantial implications for the company and its investors.

Timeline of Events

In February 2025, Aardvark went public, selling shares at $16.00 each, successfully raising over $87 million. However, since the peak, the stock price has plummeted to about $4.57 by May 2026. This dramatic decline of approximately 71.4% has raised concerns among investors, particularly following serious challenges that arose during clinical trials for ARD-101.

On May 20, 2025, during an investor conference, Jones portrayed ARD-101 as having a "very, very clean" safety profile, asserting minimal risks of adverse events. Such statements suggested a robust drug safety standard, which led many investors to buy shares in anticipation of a successful rollout. However, by February 27, 2026, Aardvark announced a voluntary hold on its pivotal Phase 3 HERO trial due to the emergence of reversible cardiac observations. This decision prompted a sharp drop in stock value, which fell by over 56%. Following that, on May 14, the FDA issued a full clinical hold on the drug, leading to an additional decline in AARD’s stock price.

Legal Proceedings and Allegations

The class action leverages claims under various sections of the Exchange Act and the Securities Act. These include allegations that Jones’s public statements regarding the drug’s safety were misleading and unduly optimistic, resulting in inflated stock prices until the reality of safety risks surfaced. Joseph E. Levi, the firm representing the aggrieved investors, emphasizes that company officers are responsible for the accuracy of their public disclosures, particularly regarding drug safety profiles.

The lawsuit argues that Aardvark’s conduct not only harmed investors financially but also raises questions about the integrity of the company’s clinical claims—misleading investors about the anticipated safety and operational timeline of ARD-101.

Next Steps for Investors

Investors who believe they may have suffered losses due to the alleged misconduct are urged to participate by gathering brokerage records that document purchase dates and quantities of their shares. Those who sold their shares at a loss during the class period might still be eligible to recover damages. Contact information has been provided for investors who wish to explore their eligibility in this class action.

As the lawsuit unfolds, further details regarding the allegations and the extent of any damages incurred by investors will surely emerge, potentially setting a precedent for how securities fraud cases involving pharmaceutical companies are handled in the future.

Conclusion

The case against Aardvark Therapeutics highlights critical issues surrounding transparency and honesty in pharmaceutical trials. Investors are advised to stay informed about the progress of this lawsuit, as its outcome could influence their financial investments and trust in pharmaceutical disclosures moving forward. It is advisable for those affected to consult with a legal expert to navigate the complexities of securities litigation and to protect their rights as shareholders.